# Opus Genetics Inc. (IRD) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $4.67, market value $389 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Opus Genetics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 39.4×**. Each dollar of revenue is priced at 39.4×, a level that requires very high margins or very fast growth to justify.

## Profitability
- **Operating margin: -513.5%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -349.3%**. The company reported a net loss over the last twelve months.
- **Return on equity: -323.1%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: 139.7%**. Return on all capital, debt included, is 139.7%: comfortably above what that capital costs.
- **Return on assets: -214.2%**. Each dollar of assets produces -214.2% of profit.

## Growth
- **Revenue growth (1 yr): 29.1%** (3-yr -29.1%/yr). Revenue grew 29.1% over the last year.
- **EPS growth (1 yr): 62.8%**. Earnings per share rose 62.8%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.07**. Debt is 0.07 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 0.9×**. It would take 0.9 years of operating earnings to repay net borrowings, within the comfortable range.
- **Altman Z-score: 4.86**. A Z-score of 4.86 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Opus Genetics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (17 analysts). 17 analysts cover Opus Genetics Inc.; the consensus is strong_buy, with an average price target of $10.71 (+129% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 264.8%** (YTD 132.3%, 3-mo 15.9%). The shares are up 264.8% over twelve months including dividends.
- **From 52-week high: -19.6%** (264.8% above the low). Trading 20% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 69**. An RSI of 69 is neutral.
- **Beta (1 yr): 1.25** (volatility 76%). Beta of 1.25 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=IRD · Page: https://foliofundamentals.com/stocks/ird

Not investment advice.